Imperial College London
Portrait Picture

Dr Charlotte-Eve Short

Faculty of Medicine, Department of Infectious Disease

Academic Clinical Lecturer
 
 
 
//

Contact

 

c.short CV

 
 
//

Location

 

VD4, Variety wingNorfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Short:2014:10.1111/hiv.12083,
author = {Short, C-ES and Douglas, M and Smith, JH and Taylor, GP},
doi = {10.1111/hiv.12083},
journal = {HIV Medicine},
pages = {233--238},
title = {Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission},
url = {http://dx.doi.org/10.1111/hiv.12083},
volume = {15},
year = {2014}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ObjectivesThe aim of the study was to describe the relationship between preterm delivery (PTD; < 37 weeks of gestation) and antiretroviral therapy in a singlecentre cohort of pregnant women with HIV infection.MethodsA retrospective analysis of data for 331 women who received care in a dedicated HIV antenatal clinic between 1996 and 2010 was carried out. Data on first CD4 cell count and viral load (HIV1 RNA copies/mL) recorded in pregnancy, class and timing of antiretroviral therapy, gestational age at delivery, and risk factors for and causes of PTD were available from a clinical database.ResultsOverall, 13.0% of deliveries were preterm, of which 53% were severe preterm (< 34 weeks of gestation). The lowest rate of PTD was observed in women treated with zidovudine monotherapy (6.2%). Higher rates of PTD were observed in women starting combination antiretroviral therapy (cART) in pregnancy compared with women conceiving while on cART [odds ratio (OR) 2.52; 95% confidence interval (CI) 1.22–5.20; P = 0.011]. Of the women who were eligible for zidovudine monotherapy on the basis of CD4 counts and HIV viral load but who were treated with shortterm cART to prevent HIV mothertochild transmission, 28.6% delivered preterm. Women on shortterm cART remained at the highest risk of PTD compared with zidovudine monotherapy in multivariate analysis (OR 5.00; 95% CI 1.49–16.79; P = 0.015).ConclusionsThe causes of PTD are multiple and poorly understood. The timing of initiation and type of antiretroviral therapy administered during pregnancy appear to contribute to PTD risk. Understanding this association should improve the safety of antiretroviral therapy in pregnancy without increasing the risk of transmission.
AU  - Short,C-ES
AU  - Douglas,M
AU  - Smith,JH
AU  - Taylor,GP
DO  - 10.1111/hiv.12083
EP  - 238
PY  - 2014///
SN  - 1464-2662
SP  - 233
TI  - Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission
T2  - HIV Medicine
UR  - http://dx.doi.org/10.1111/hiv.12083
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000332074300006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/full/10.1111/hiv.12083
VL  - 15
ER  -
Download